Treatment of resistant depression by adding noradrenergic agents to lithium augmentation of SSRIs

Annals of Pharmacotherapy

Volumn 36, Issue 4, 2002, Pages 634-640

  Ramasubbu, Rajamannar ^a   Suárez, Encarnación C ^a   Vanier, Marie Claude ^a  

^a FOOTHILLS HOSPITAL   (Canada)

Author keywords

Lithium carbonate; Noradrenergic antidepressants; Resistant depression; Selective serotonin reuptake inhibitors

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CLONAZEPAM; DESIPRAMINE; FLUOXETINE; LEVOMEPROMAZINE; LITHIUM; LITHIUM CARBONATE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PAROXETINE; PINDOLOL; PROPRANOLOL; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRYPTOPHAN; ZOPICLONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DEPRESSION; DOSE CALCULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; DYSTHYMIA; FEMALE; HEADACHE; HUMAN; INSOMNIA; MALE; NAUSEA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; REMISSION; TINNITUS; TREATMENT OUTCOME; TREMOR;

EID: 0036205957     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10408     Document Type: Article

References (36)

1. Lithium augmentation in sertraline-resistant depression: A preliminary dose-response study
2. Variability of response to lithium augmentation in refractory depression
3. Antidepressant augmentation: Conclusions and recommendations
4. Augmentation strategies with serotonin-noradrenergic combinations
5. Bupropion: A review of its mechanism of antidepressant activity
6. Combination treatment with noradrenergic and serotonin reuptake inhibitors in resistant depression
7. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy
8. CGI - Clinical global impression
9. Treatment resistant depression
10. Trazodone: A review of its pharmacological properties and therapeutic use in depression and anxiety
11. Poor response to fluoxetine: Underlying depression, serotonergic over-stimulation, or a "therapeutic window"?
12. Serotonergic synergism: The risks and benefits of combining selective serotonin reuptake inhibitors with other serotonergic drugs
13. Estrogen augments serotonergic activity in postmenopausal women
14. Increased antidepressant use in patients prescribed β-blockers
15. Clonazepam: New uses and potential problems
16. Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients
17. Nefazadone versus sertraline in out patients with major depression: Focus on efficacy, tolerability and effects on sexual function and satisfaction
18. A comparison of nefazodone and fluoxetine on mood and on objective, subjective, and clinician-rated measures of sleep in depressed patients: A double-blind, 8-week clinical trial
19. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression
20. The use of pindolol to potentiate antidepressant medication
21. The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double blind, placebo-controlled trial
22. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: A double-blind study
23. Treatment research at the millennium: From efficacy to effectiveness
24. Lithium or desipramine augmentation of fluoxetine treatment
25. Lithium carbonate augmentation of desipramine and fluoxetine in refractory depression
26. Clinical pharmacokinetics of selective serotonin reuptake inhibitors
27. Role of norepinephrine in the pathophysiology and treatment of mood disorders
28. Do noradrenergic and serotonin differentially affect social motivation and behaviour?
29. Short term lithium administration enhances serotonergic neurotransmission: Electrophysiologic evidence in rat CNS
30. Clinical implications of research on the mechanism of action of lithium
31. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites
32. 5-Hydroxy tryptamine-2 and beta-adrenergic receptor regulation in rat brain following chronic treatment with desipramine and fluoxetine alone and in combination
33. 2 receptor binding in patients with major depression following desipramine treatment: A position emission tomography study with fluorine-18-labeled setoperone
34. A molecular and cellular theory of depression
35. Blue genes and monoamine hypothesis of depression